Organization

TAMIRNA GMBH

Austrian biotech SME developing miRNA-based diagnostic tests for osteoporosis, fracture risk, and translational safety biomarkers.

Technology SMEhealthATSMENo active H2020 projects

H2020 projects

As coordinator

Total EC funding

€1.7M

Unique partners

What they do

Their core work

TAmiRNA is a Vienna-based biotech SME specializing in microRNA (miRNA)-based diagnostic tests, with a core focus on bone health and osteoporosis. Their flagship product, OsteomiR-Test, is an in-vitro diagnostic for osteoporosis and fracture risk assessment using circulating miRNA biomarkers. Beyond bone diagnostics, they contribute miRNA biomarker expertise to large-scale translational safety and personalized medicine consortia, positioning themselves as a specialized biomarker technology provider for pharmaceutical and clinical research applications.

Core expertise

What they specialise in

miRNA-based diagnostics for bone healthprimary

3 projects

Core to all three projects: OsteomiR (osteoporosis diagnosis), FIDELIO (bone fragility in diabetes), and TransBioLine (biomarker pipeline including miRNAs)

Osteoporosis and fracture risk assessmentprimary

2 projects

OsteomiR focused specifically on in-vitro osteoporosis diagnosis; FIDELIO addresses bone fragility and fractures in diabetic patients

Translational safety biomarkerssecondary

1 project

TransBioLine (€1.34M funding) focuses on drug safety biomarker qualification and regulatory implementation

Personalized medicine in metabolic diseaseemerging

1 project

FIDELIO integrates diabetes, microbiome, gene-environment interactions, and personalized medicine approaches to bone fragility

Evolution & trajectory

How they've shifted over time

Early focus

Osteoporosis diagnostics

Recent focus

Translational biomarkers and metabolic disease

TAmiRNA began in 2015 with a focused SME Phase 1 feasibility study (OsteomiR) to validate their core miRNA-based osteoporosis diagnostic. By 2019, they had expanded into two larger consortia — TransBioLine for drug safety biomarkers and FIDELIO for diabetes-related bone disease — both leveraging their miRNA platform but applying it to broader clinical contexts. The trajectory shows a classic SME growth pattern: from single-product validation to becoming a recognized biomarker technology partner embedded in major European research networks.

TAmiRNA is expanding from a single-indication diagnostic company toward a platform biomarker provider across drug safety and metabolic disease, making them increasingly relevant for pharma and clinical trial partnerships.

Collaboration profile

How they like to work

Role: specialist_contributorReach: European12 countries collaborated

TAmiRNA started as a coordinator of their own feasibility study (OsteomiR, SME-1) and then joined two large Research and Innovation Actions as a specialist participant. With 37 unique partners across 12 countries from just 3 projects, they operate within broad European consortia rather than small bilateral collaborations. This profile suggests a company that brings a specific technology capability (miRNA biomarker expertise) to large interdisciplinary teams — easy to integrate as a specialist partner.

Despite only three projects, TAmiRNA has built a surprisingly wide network of 37 partners across 12 countries, reflecting their participation in large multi-site translational research consortia focused on biomarkers and clinical validation.

Why partner with them

What sets them apart

TAmiRNA occupies a niche at the intersection of miRNA biology and clinical diagnostics for bone disease — a combination few European SMEs offer. Their progression from feasibility study to major consortium partner in drug safety biomarkers demonstrates both scientific credibility and commercial readiness. For consortium builders, they bring a validated biomarker technology platform that can be applied across indications, not just a research idea.

Notable projects

Highlights from their portfolio

TransBioLine
Largest funding (€1.34M) — a major translational biomarker pipeline project signaling TAmiRNA's recognition as a key biomarker technology provider in drug safety
OsteomiR
Their origin project as coordinator — SME Phase 1 feasibility study for their core miRNA osteoporosis diagnostic, demonstrating entrepreneurial initiative
FIDELIO
MSCA training network linking bone fragility to diabetes, microbiome, and personalized medicine — shows TAmiRNA's miRNA expertise extending into complex multi-system disease

Cross-sector capabilities

Pharmaceutical drug safety and toxicologyClinical diagnostics and in-vitro testingPersonalized medicine and precision healthMetabolic disease research (diabetes, osteoporosis)

Analysis note: Profile based on only 3 H2020 projects. The early-period keyword data was empty (OsteomiR had no keywords in the dataset), so evolution analysis relies on project titles and dates rather than keyword shift analysis. The company name itself ("TAmiRNA") and product name ("OsteomiR-Test") provide strong contextual signals about their core expertise. Commercial status and current product availability could not be verified from H2020 data alone.